China 
Africa 
Explore chapters and articles related to this topic
Nanoparticles from Marine Biomaterials for Cancer Treatment
Published in Se-Kwon Kim, Marine Biochemistry, 2023
The U.S. Food and Drug Administration (FDA) has approved a number of important anticancer drugs derived from marine organisms, such as cytarabine (Cytosar U®), a chemotherapeutic drug used to treat leukemia. Trabectedin (Yondelis®) is another antitumor agent that is used to treat advanced soft tissue sarcoma. Breast, prostate, and pediatric sarcomas are all in clinical studies. Another anticancer medication, eribulin mesylate (Halaven®), is used to treat breast cancer and liposarcoma. Brentuximab vedotin (Adcetris®) is an antibody-drug conjugate (ADC) medication used to treat HL and anaplastic large cell lymphoma that has relapsed or become resistant. Midostaurin (Rydapt®) is a protein kinase inhibitor used to treat acute myeloid leukemia and myelodysplastic syndrome (van Andel et al. 2018). Furthermore, 19 anticancer substances obtained from the sea are at various stages of clinical testing (Zuo and Kwok 2021). Numerous studies have also demonstrated the anticancer properties of marine-derived chemicals in vitro or in vivo.
Precision or Personalized Medicine for Cancer Chemotherapy: Is There a Role for Herbal Medicine?
Published in Shaker A. Mousa, Raj Bawa, Gerald F. Audette, The Road from Nanomedicine to Precision Medicine, 2020
Zhijun Wang, Xuefeng Liu, Rebecca Lucinda Ka Yan Ho, Christopher Wai Kei Lam, Moses Sing Sum Chow
Since cancer chemotherapy often involves drug combination, a unified approach to optimize multidrug chemotherapy using a pharmacokinetic enhanced pharmacodynamic model has been developed. This model is based on the vascular endothelial growth factor receptor (VEGFR) signaling system characterized by ligand-receptor interactions, enzyme recruitment (Grb2-Sos, phospholipase Cγ (PLCγ), and phosphoinositide-3 kinase (PI3K)), and downstream mitogen-activated protein kinase and Akt cascade activation. Drugs targeting these mechanisms (a VEGF inhibitor, a PI3K inhibitor, a PLCγ inhibitor, and a mitogen-activated protein kinase inhibitor) and sunitinib can provide input to optimization-based control analyses. This method can capture the complexities of drug action, tailor cancer chemotherapy, and empower personalized medicine [56].
Precision or Personalized Medicine for Cancer Chemotherapy: Is There a Role for Herbal Medicine?
Published in Shaker A. Mousa, Raj Bawa, Gerald F. Audette, The Road from Nanomedicine to Precision Medicine, 2019
Zhijun Wang, Xuefeng Liu, Rebecca Lucinda Ka Yan Ho, Christopher Wai Kei Lam, Moses Sing Sum Chow
Since cancer chemotherapy often involves drug combination, a unified approach to optimize multidrug chemotherapy using a pharmacokinetic enhanced pharmacodynamic model has been developed. This model is based on the vascular endothelial growth factor receptor (VEGFR) signaling system characterized by ligand-receptor interactions, enzyme recruitment (Grb2-Sos, phospholipase Cγ (PLCγ), and phosphoinositide-3 kinase (PI3K)), and downstream mitogen-activated protein kinase and Akt cascade activation. Drugs targeting these mechanisms (a VEGF inhibitor, a PI3K inhibitor, a PLCγ inhibitor, and a mitogen-activated protein kinase inhibitor) and sunitinib can provide input to optimization-based control analyses. This method can capture the complexities of drug action, tailor cancer chemotherapy, and empower personalized medicine [56].
An insight on the different synthetic routes for the facile synthesis of O/S-donor carbamide/thiocarbamide analogs and their miscellaneous pharmacodynamic applications
Published in Journal of Sulfur Chemistry, 2023
Faiza Asghar, Bushra Shakoor, Babar Murtaza, Ian S. Butler
Protein kinase inhibitors block the action of protein kinases that are being involved in phosphorylation (addition of phosphate group to a protein), which in turn became the protein effective or ineffective and, therefore, affects its level of activity and function. Protein kinase dysfunction is accompanied with the access of numerous human diseases including cancer, inflammatory disorders, autoimmune syndromes, and cardiac diseases. Thus, the inhibition of the enzymes that initiate phosphorylation offers an approach to treat such diseases [116].